http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:09:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24125+at+Truist+Securities/26776584.html Truist Securities analyst Richard Newitter raised the price target on Lantheus Holdings (NASDAQ: LNTH) to $125.00 (from $115.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24125+at+Truist+Securities/26776584.html Thu, 16 Jul 2026 07:09:48 -0400 LNTH http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769